Reshaping Risk/Reward in Biotech VC
As returns from internet start-ups continue to reshape venture capital, the risk/reward ratios for biotech companies become less attractive for VC's. Since the biotechnology industry plays a direct role in improving health care, perhaps what's needed are investment incentives provided by public policy.
You may also be interested in...
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
The FDA wants to know if the second letter in its product equivalence ratings system is helpful and whether changes could make the information more user-friendly.
From digital marketing to payment systems, electronic solutions are aiding Indian pharma ensure business continuity during the lockdown. As new guidelines spur adoption of telemedicine and digital tools connect a company to its distribution chain and healthcare professionals, experts say some changes are here to stay while others might not stick